Stryker Corporation operates as a medical technology company. The company operates through three segments: Orthopaedics, MedSurg, and Neurotechnology and Spine. The Orthopaedics segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. The MedSurg segment offers surgical equipment and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, and other medical devices for use in various medical specialties. The Neurotechnology and Spine segment provides neurotechnology products that include products used for minimally invasive endovascular techniques; products for brain and open skull based surgical procedures; orthobiologic and biosurgery products, such as synthetic bone grafts and vertebral augmentation products; and minimally invasive products for the treatment of acute ischemic and hemorrhagic stroke. It also provides spinal implant products comprising cervical, thoracolumbar, and interbody systems for use in spinal injury, deformity, and degenerative therapies. The company sells its products to doctors, hospitals, and other healthcare facilities through company-owned sales subsidiaries and branches, as well as third-party dealers and distributors in approximately 85 countries. Stryker Corporation was founded in 1941 and is headquartered in Kalamazoo, Michigan.
Industry, Sector and Symbol
Stock Exchange NYSE
Industry Surgical & medical instruments
Sub-IndustryHealth Care Equipment
SectorMedical
SymbolNYSE:SYK
CUSIP86366710
Phone269-389-2600
Debt
Debt-to-Equity Ratio0.63
Current Ratio1.83
Quick Ratio1.15
Price-To-Earnings
Trailing P/E Ratio26.10
Forward P/E Ratio24.15
P/E Growth2.49
Sales & Book Value
Annual Sales$12.44 billion
Price / Sales5.26
Cash Flow$8.1822 per share
Price / Cash21.40
Book Value$26.67 per share
Price / Book6.57
Profitability
EPS (Most Recent Fiscal Year)$6.49
Net Income$1.02 billion
Net Margins8.28%
Return on Equity26.93%
Return on Assets12.05%
Miscellaneous
Employees33,000
Outstanding Shares373,990,000
Market Cap$66.45 billion
Stryker (NYSE:SYK) Frequently Asked Questions
What is Stryker's stock symbol?
Stryker trades on the New York Stock Exchange (NYSE) under the ticker symbol "SYK."
How often does Stryker pay dividends? What is the dividend yield for Stryker?
Stryker announced a quarterly dividend on Wednesday, September 19th. Stockholders of record on Friday, September 28th will be given a dividend of $0.47 per share on Wednesday, October 31st. This represents a $1.88 dividend on an annualized basis and a dividend yield of 1.07%. The ex-dividend date of this dividend is Thursday, September 27th. View Stryker's Dividend History.
How were Stryker's earnings last quarter?
Stryker Co. (NYSE:SYK) issued its quarterly earnings results on Tuesday, July, 24th. The medical technology company reported $1.76 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.73 by $0.03. The medical technology company had revenue of $3.32 billion for the quarter, compared to analysts' expectations of $3.31 billion. Stryker had a net margin of 8.28% and a return on equity of 26.93%. Stryker's revenue was up 10.3% on a year-over-year basis. During the same quarter last year, the company posted $1.53 EPS. View Stryker's Earnings History.
When is Stryker's next earnings date?
How can I listen to Stryker's earnings call?
Stryker will be holding an earnings conference call on Thursday, October 25th at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link or dial in at 8448260610.
What guidance has Stryker issued on next quarter's earnings?
Stryker updated its FY18 earnings guidance on Tuesday, July, 24th. The company provided earnings per share (EPS) guidance of $7.22-7.27 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $7.23. Stryker also updated its Q3 guidance to $1.65-1.70 EPS.
What price target have analysts set for SYK?
22 brokers have issued 1 year price targets for Stryker's shares. Their forecasts range from $165.00 to $200.00. On average, they expect Stryker's stock price to reach $180.45 in the next year. This suggests a possible upside of 3.1% from the stock's current price. View Analyst Price Targets for Stryker.
What is the consensus analysts' recommendation for Stryker?
22 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Stryker in the last year. There are currently 7 hold ratings and 15 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Stryker.
What are Wall Street analysts saying about Stryker stock?
Here are some recent quotes from research analysts about Stryker stock:
- 1. BTIG Research analysts commented, "Adding Photonics to its Instrument Offerings This morning, Stryker announced the acquisition of Invuity (IVTY, Not a share in all cash, for a deal value of ~$190M. With TTM sales of $40.8M, the deal multiple comes in at ~4.7x, in line with previous SYK acquisitions. The IVTY portfolio of photonic illuminated retractors will add to Stryker’s product offering in a variety of areas such as nipple- sparing mastectomies, anterior hip procedures, as well as general surgery and other areas. We believe the IVTY products will compliment Stryker’s existing visualization and illumination product portfolio modestly. That said, while IVTY offered a novel technology, the company was challenged to independently gain broader adoption as a stand-alone technology beyond a specific subset of procedures where proper illumination was not achieved with overhead exterior surgical field lighting." (9/12/2018)
- 2. Needham & Company LLC analysts commented, "SYK is acquiring Invuity (IVTY) for $7.40 per share (a 29% premium) or ~$190M of cash which is 3.4x consensus 2019E sales (vs. 6.4x EV/2019E sales for its medical supplies peers). IVTY makes disposable lighted instruments which increase visibility during minimally invasive surgical (MIS) procedures. We believe IVTY fits well with SYK’s Instruments business and note that IVTY’s products are applicable to a large number of surgical procedures. While the deal may be slightly dilutive in 2019, we believe that SYK can absorb this and still deliver on its 9%+ EPS growth target. And the deal should start to become increasingly accretive in 2020 and beyond." (9/11/2018)
- 3. According to Zacks Investment Research, "Stryker wrapped up the second quarter on a solid note, with earnings and revenues beating estimates. The company continues to gain from its flagship Mako Total Knee platform, which drove its core Orthopaedic segment. In fact, Mako saw increasing robot installations in the quarter. Surging domestic sales is a positive. Moreover, solid performance in emerging markets and Europe paints a bright picture. Considerable expansion in operating margin is encouraging as well. Higher R&D expenses indicate increasing focus on innovation. However, Stryker’s Spine business continued to see market softness and mid-single digit pricing declines. Further, supply issues in the Puerto Rico facility continue to plague the company. The slowdown of MedSurg’s sustainability revenue growth is another negative. Stiff competition is likely to mar Stryker’s prospects. Stryker underperformed the industry in a year." (8/8/2018)
- 4. Cantor Fitzgerald analysts commented, ". This morning (6/11), Journal reported that SYK made a takeover approach of Boston Scientific (Not Covered). Trading on both stocks was halted for a period of time during the day. BSX released an 8-K saying that it was aware of the story, but in accordance with company practice, it does not comment on market rumors or speculation. SYK made similar comment when we reached out directly to them. We view SYK’s potential interest positively, although as somewhat unexpected." (6/13/2018)
Who are some of Stryker's key competitors?
Some companies that are related to Stryker include 3M (MMM), Becton Dickinson and (BDX), Boston Scientific (BSX), Baxter International (BAX), FRESENIUS SE &/S (FSNUY), ABIOMED (ABMD), ResMed (RMD), DexCom (DXCM), Teleflex (TFX), Hill-Rom (HRC), Insulet (PODD), Haemonetics (HAE), ICU Medical (ICUI), Integra Lifesciences (IART) and Globus Medical (GMED).
Who are Stryker's key executives?
Stryker's management team includes the folowing people:
- Mr. Kevin A. Lobo, Chairman & CEO (Age 53)
- Mr. Timothy J. Scannell, Pres & COO (Age 53)
- Mr. Glenn S. Boehnlein, VP & CFO (Age 56)
- Mr. Lonny J. Carpenter, Group Pres & Adviser to the CEO (Age 56)
- Mr. David K. Floyd, Group Pres & Advisor to the CEO (Age 57)
Who are Stryker's major shareholders?
Stryker's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Bank of Montreal Can (0.10%), Nisa Investment Advisors LLC (0.04%), Wendell David Associates Inc. (0.03%), Chesley Taft & Associates LLC (0.03%), Capital Investment Services of America Inc. (0.02%) and Campbell Newman Asset Management Inc. (0.02%). Company insiders that own Stryker stock include David Floyd, Glenn S Boehnlein, Graham A Mclean, Howard E Cox Jr, Katherine Ann Owen, Kevin Lobo, Lonny J Carpenter, Louise Francesconi, M Kathryn Fink, Roch Doliveux, Ronda E Stryker, Timothy J Scannell, William E Berry Jr and Yin C Becker. View Institutional Ownership Trends for Stryker.
Which major investors are selling Stryker stock?
SYK stock was sold by a variety of institutional investors in the last quarter, including Private Capital Advisors Inc., JLB & Associates Inc., Addenda Capital Inc., Essex Investment Management Co. LLC, Steigerwald Gordon & Koch Inc., Douglass Winthrop Advisors LLC, Iberiabank Corp and Capital Investment Services of America Inc.. Company insiders that have sold Stryker company stock in the last year include David Floyd, Glenn S Boehnlein, Graham A Mclean, Howard E Cox Jr, Katherine Ann Owen, Kevin Lobo, Lonny J Carpenter, M Kathryn Fink, William E Berry Jr and Yin C Becker. View Insider Buying and Selling for Stryker.
Which major investors are buying Stryker stock?
SYK stock was purchased by a variety of institutional investors in the last quarter, including Bank of Montreal Can, Stock Yards Bank & Trust Co., Cobiz Wealth LLC, Trust Department MB Financial Bank N A, Nisa Investment Advisors LLC, MainStreet Investment Advisors LLC, First Hawaiian Bank and Andra AP fonden. View Insider Buying and Selling for Stryker.
How do I buy shares of Stryker?
Shares of SYK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Stryker's stock price today?
One share of SYK stock can currently be purchased for approximately $175.10.
How big of a company is Stryker?
Stryker has a market capitalization of $66.45 billion and generates $12.44 billion in revenue each year. The medical technology company earns $1.02 billion in net income (profit) each year or $6.49 on an earnings per share basis. Stryker employs 33,000 workers across the globe.
What is Stryker's official website?
How can I contact Stryker?
Stryker's mailing address is 2825 AIRVIEW BLVD, KALAMAZOO MI, 49002. The medical technology company can be reached via phone at 269-389-2600 or via email at [email protected]
MarketBeat Community Rating for Stryker (NYSE SYK)
MarketBeat's community ratings are surveys of what our community members think about Stryker and other stocks. Vote "Outperform" if you believe SYK will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SYK will underperform the S&P 500 over the long term. You may vote once every thirty days.
